16.43  0.22 (1.36%)		10-15 12:12
Open: 16.25 High: 16.45 Volume: 96,254		Pre. Close: 16.21 Low: 16.25 Market Cap: 474(M)

Short term
Mid term
Targets	6-month :	19.2	1-year :	22.42
Resists	First :	16.44	Second :	19.2
Pivot price	15.69
Supports	First :	14.85	Second :	13.88
MAs	MA(5) :	16.18	MA(20) :	15.31
	MA(100) :	13.67	MA(250) :	13.55
MACD	MACD :	0.5	Signal :	0.5
%K %D	K(14,3) :	97.7	D(3) :	95.2
RSI	RSI(14): 80
52-week	High :	16.44	Low :	10.55

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ HQL ] has closed below upper band by 14.7%. Bollinger Bands are 111.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	16.32 - 16.38	16.38 - 16.43
Low:	15.88 - 15.95	15.95 - 16.01
Close:	16.09 - 16.21	16.21 - 16.31

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

Wed, 17 Sep 2025
Vaxart Appoints W. Mark Watson as Lead Independent Director - The Globe and Mail

Thu, 21 Dec 2023
HQH: Remains Beaten Down But Also Remains An Interesting Prospect - Seeking Alpha

Fri, 27 Oct 2023
abrdn Announces Its Appointment to Four U.S. Specialist Healthcare Closed-End Funds, New Board of Trustees to the Funds and Fund Name Changes - Yahoo Finance

Sun, 05 Mar 2023
Tekla Healthcare Investors: Higher Risk Healthcare CEF - Seeking Alpha

Tue, 16 Aug 2022
Tekla Life Sciences Investors Declares Distribution | User | woonsocketcall.com - FinancialContent

Fri, 31 Dec 2021
Tekla Life Sciences Investors Paid Distribution - FinancialContent

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Financial Services
Industry: Asset Management
Shares Out	29 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	30.9 (%)
Shares Short	38 (K)
Shares Short P.Month	77 (K)

EPS	-0.48
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	13.71
Profit Margin	0 %
Operating Margin	-101 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	-34.1 %
Gross Profit (p.s.)	0.11
Sales Per Share	0.11
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-34.25
PEG Ratio	0
Price to Book value	1.19
Price to Sales	144.66
Price to Cash Flow	0

Dividend	0.41
Forward Dividend	0
Dividend Yield	2.5%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.